A PYMNTS Company

Pharmaceutical Antitrust Complexity

By  |  December 2, 2014

Posted by Social Science Research Network

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Pharmaceutical Antitrust Complexity – Michael A. Carrier (Rutgers University School of Law – Camden)

    ABSTRACT: The pharmaceutical industry is unique in its complexity. Markets are nuanced. Multiple regulatory regimes apply. Generic entry is an event with dramatic consequences. These characteristics have encouraged brand-name drug firms to engage in an array of conduct that exploits this complexity to delay generic entry.

    This essay discusses these issues, focusing on two activities: (1) “product hopping” from one version of a drug to another and (2) settlements by which brands pay generics to delay entry.